Friedreich's ataxia: Clinical pilot trial with recombinant human erythropoietin

Annals of Neurology

Volumn 62, Issue 5, 2007, Pages 521-524

  Boesch, Sylvia ^a   Sturm, Brigitte ^b   Hering, Sascha ^a   Goldenberg, Hans ^b   Poewe, Werner ^a   Scheiber Mojdehkar, Barbara ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; CREATININE; FRATAXIN; NEORECORMONE; PEROXIDE; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD PRESSURE FLUCTUATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE MARKER; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRIEDREICH ATAXIA; HUMAN; MALE; OPEN STUDY; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FRIEDREICH ATAXIA; HUMANS; IRON-BINDING PROTEINS; MALE; MIDDLE AGED; PILOT PROJECTS;

EID: 37349059308     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.21177     Document Type: Article

References (20)

1. Harding AE. Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain 1981;104:589-620.
2. Mateo I, Llorca J, Volpini V, et al. Expanded GAA repeats and clinical variation in Friedreich's ataxia. Acta Neurol Scand 2004;109:75-78.
3. Campuzano V, Montermini L, Molto MD, et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 1996;271:1423-1427.
4. Campuzano V, Montermini L, Lutz Y, et al. Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum Mol Genet 1997;6:1771-1780.
5. Tan G, Chen LS, Lonnerdal B, et al. Frataxin expression rescues mitochondrial dysfunctions in FRDA cells. Hum Mol Genet 2001;10:2099-2107.
6. Bogoyevitch MA. An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection. Cardiovasc Res 2004;63:208-216.
7. Juul S. Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage. Acta Paediatr Suppl 2002;91:36-42.
8. Li W, Maeda Y, Yuan RR, et al. Beneficial effect of erythropoietin on experimental allergic encephalomyelitis. Ann Neurol 2004;56:767-777.
9. Siren AL, Ehrenreich H. Erythropoietin - a novel concept for neuroprotection. Eur Arch Psychiatry Clin Neurosci 2001;251:179-184.
10. Sturm B, Stupphann D, Kaun C, et al. Recombinant human erythropoietin: effects on frataxin expression in vitro. Eur J Clin Invest 2005;35:711-717.
11. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 2001;412:641-647.
12. Masuda S, Nagao M, Takahata K, et al. Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J Biol Chem 1993;268:11208-11216.
13. Grasso G, Buemi M, Alafaci C, et al. Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage. Proc Natl Acad Sci U S A 2002;99:5627-5631.
14. Squadrito F, Altavilla D, Squadrito G, et al. Recombinant human erythropoietin inhibits iNOS activity and reverts vascular dysfunction in splanchnic artery occlusion shock. Br J Pharmacol 1999;127:482-488.
15. Chong ZZ, Kang JQ, Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 2002;106:2973-2979.
16. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 2000;97:10526-10531.
17. Shingo T, Sorokan ST, Shimazaki T, et al. Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J Neurosci 2001;21:9733-9743.
18. Calapai G, Marciano MC, Corica F, et al. Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation. Eur J Pharmacol 2000;401:349-356.
19. Kawakami M, Sekiguchi M, Sato K, et al. Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia. J Biol Chem 2001;276:39469-39475.
20. Schulz JB, Dehmer T, Schols L, et al. Oxidative stress in patients with Friedreich ataxia. Neurology 2000;55:1719-1721.